PEAR1 (Platelet Endothelial Aggregation Receptor 1) is a transmembrane protein that plays a significant role in cellular signaling, particularly in platelet function and endothelial cell communication. PEAR1 inhibitors refer to a chemical class that specifically interferes with the activity of this receptor, potentially altering cellular responses related to signaling cascades initiated by the receptor. The PEAR1 protein is primarily expressed on the surface of platelets and endothelial cells, and it has been found to mediate responses to extracellular stimuli by influencing intracellular signaling pathways such as those involving calcium mobilization, PI3K/AKT, and MAPK. PEAR1 inhibitors are designed to disrupt this receptor-ligand interaction, thereby modulating the downstream effects triggered by PEAR1 activation, including those that regulate cell adhesion, proliferation, and survival in various biological environments.
The chemical characteristics of PEAR1 inhibitors vary widely depending on the structure of the compound and its mechanism of action. Many of these inhibitors function by binding to the extracellular domain of the receptor, thus preventing the receptor from interacting with its ligands. Others may affect the intracellular domains, altering the receptor's ability to transmit signals. Inhibitors can be small molecules, peptides, or other synthetic compounds that target the PEAR1 signaling pathway. The selectivity and specificity of PEAR1 inhibitors are often achieved through precise modifications of their chemical structure, ensuring that they interact only with the desired target receptor. Understanding the precise molecular interactions between these inhibitors and PEAR1 is critical for assessing their efficiency in modulating receptor function and their impact on cellular behavior. Advanced studies on PEAR1 inhibitors frequently involve techniques such as molecular docking, crystallography, and structure-activity relationship (SAR) analysis to optimize their binding affinity and specificity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
May inhibit the tyrosine kinase activity involved in the expression regulation of PEAR1, potentially altering platelet activation pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Could target multiple kinases, potentially affecting signaling pathways that regulate PEAR1 expression in platelets. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Might inhibit Src kinase activity, affecting signaling pathways involved in the regulation of PEAR1 expression. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
By inhibiting EGFR, it might alter pathways that could influence the expression of PEAR1 in cells. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
As a multi-targeted kinase inhibitor, it could impact several pathways influencing the expression of PEAR1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Could influence PEAR1 expression through its activity on various cellular signaling pathways, including those involved in inflammation. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Might modulate PEAR1 expression by affecting transcription factors and cellular redox status. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
By inhibiting EGFR and HER2, it could impact signaling pathways that might influence PEAR1 expression. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Could influence PEAR1 expression by inhibiting VEGFR, RET, and EGFR, thus affecting multiple signaling pathways. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Might affect PEAR1 expression through its activity as a selective BCR-ABL inhibitor, influencing related signaling pathways. | ||||||